Emergent BioSolutions Signs $174M Agreement To Expand Production Of Possible Coronavirus Vaccine

A Maryland-based company has signed a $174 million agreement to expand production of a coronavirus vaccine candidate. Gaithersburg-based Emergent BioSolutions announced on Monday it had signed the agreement to develop and manufacture AstraZeneca’s possible COVID-19 vaccine. Under the agreement, manufacturing will begin at Emergent’s Bayview facility in Baltimore. (WJZ-TV)

Read Full Article